Here's Why BioCryst Pharmaceuticals Jumped Higher Today
Shares of BioCryst Pharmaceuticals (NASDAQ: BCRX) are up 14.5% at 1:16 p.m. after the biotech's new CFO, Anthony Doyle, purchased 54,000 shares of the company at $4.08 per share. That's an investment of more than $220,000.
As they say, there are many reasons an executive might feel the need to sell shares, but there's only one reason to buy: Doyle clearly thinks shares are undervalued at this point.
Doyle's price is well below the company's 52-week high of $6.29, but it's also nearly three times the 52-week low of $1.38. Call it a good, but certainly not great, price.
Source Fool.com
